tiprankstipranks
Trending News
More News >
Bioventus (BVS)
NASDAQ:BVS
US Market
Advertisement

Bioventus (BVS) AI Stock Analysis

Compare
179 Followers

Top Page

BVS

Bioventus

(NASDAQ:BVS)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 4o)
Rating:53Neutral
Price Target:
$7.00
▲(1.16% Upside)
Bioventus's overall stock score is driven by a combination of financial challenges and strategic growth opportunities. The company's high leverage and declining revenue weigh heavily on its financial performance score. Technical indicators suggest a neutral to bearish trend, while valuation metrics highlight profitability concerns. However, the positive sentiment from the earnings call, with strong growth in key segments and new product opportunities, provides a counterbalance, resulting in a moderate overall score.
Positive Factors
Product Innovation
The clearance for new products in the peripheral nerve stimulation market positions Bioventus for growth in a sector expected to expand significantly, enhancing its competitive edge and market presence.
Cash Flow Improvement
Improved cash flow from operations indicates better financial health and the ability to invest in growth opportunities, reducing reliance on external financing.
Segment Growth
Strong growth in Surgical Solutions reflects effective strategy execution, enhancing Bioventus's market position and supporting sustained revenue expansion.
Negative Factors
High Leverage
High leverage poses financial risks, potentially limiting Bioventus's ability to invest in growth and increasing vulnerability to economic downturns.
Declining Revenue
A significant decline in revenue challenges Bioventus's financial stability and may hinder its ability to sustain operations and fund new initiatives.
Profitability Challenges
Negative profit margins suggest operational inefficiencies and may limit Bioventus's ability to reinvest in the business, affecting long-term growth prospects.

Bioventus (BVS) vs. SPDR S&P 500 ETF (SPY)

Bioventus Business Overview & Revenue Model

Company DescriptionBioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
How the Company Makes MoneyBioventus generates revenue through multiple streams, primarily from the sale of its medical devices, biologic products, and therapeutic solutions. The company has a strong focus on the orthopedic market, where it markets its ultrasound devices and other technologies to hospitals, clinics, and outpatient facilities. Significant partnerships with healthcare providers and distributors enhance its market reach and facilitate sales. Additionally, Bioventus may also derive income from research collaborations, licensing agreements, and product development partnerships, which further diversify its revenue sources. The company's commitment to innovation and its pipeline of new products are crucial factors contributing to its earnings potential.

Bioventus Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with strong financial results, strategic growth in key business areas, and significant opportunities from new product clearances. However, challenges from divestiture impacts, foreign exchange losses, and tariff headwinds were acknowledged.
Q2-2025 Updates
Positive Updates
Strong Financial Performance
Bioventus reported second quarter revenue of $148 million, in line with expectations and reflecting a 6% organic growth despite challenging prior year comparisons. Adjusted earnings per share increased by 31% compared to the prior year, and the adjusted EBITDA margin of 23% exemplified stability and disciplined investment in key growth strategies.
Surgical Solutions Growth
The Surgical Solutions business delivered strong double-digit growth in ultrasonics, driven by enhanced precision and control for surgeons, reduced patient blood loss, and increased operating room efficiency.
Restorative Therapies Success
Exogen accelerated and achieved double-digit growth for the quarter, validating the approach to drive success across product categories with tighter focus, right strategy, targeted investments, and disciplined commercial execution.
510(k) Clearance for Chronic Pain Treatment
Bioventus received 510(k) clearance for StimTrial and TalisMann for peripheral nerve stimulation, opening a significant growth opportunity in the fast-growing PNS market, expected to exceed $500 million by 2029.
Cash Flow and Debt Management
Cash flow from operations totaled $26 million, an increase of $11 million compared to the prior year. The company expects to nearly double cash flow from operations compared to 2024, and refinanced its credit facility with benefits like reduced interest rates and extended maturity.
Negative Updates
Impact of Divestiture and Foreign Exchange
Second quarter revenue was 2% lower than 2024 due to the impact of the Advanced Rehabilitation divestiture. Additionally, foreign currency exchange rate movements resulted in more than $2 million in impacts.
Pain Treatments Growth Challenges
Pain Treatments revenue growth slowed to 1% due to challenging comparisons to the prior year period, with efforts now focused on driving traction with large accounts and geographic expansion.
Tariff and Foreign Exchange Headwinds
The company absorbed $5 million in headwinds from tariffs and foreign exchange impacts, which are expected to continue affecting the financial outlook.
Company Guidance
During the Bioventus Inc. Second Quarter 2025 Earnings Conference Call, the company provided detailed guidance and insights into its financial performance and strategic priorities. Bioventus reported second-quarter revenue of $148 million, reflecting a 6% organic growth despite a 2% overall decline due to the divestiture of its Advanced Rehabilitation business. The company achieved adjusted earnings per share of $0.21, a 31% increase from the previous year, and an adjusted EBITDA margin of 23%. Bioventus reaffirmed its full-year 2025 guidance, expecting organic revenue growth between 6% and 8%, adjusted EBITDA of $112 million to $116 million, and EPS of $0.64 to $0.68. The company highlighted significant growth drivers, including strong double-digit growth in its Surgical Solutions and Restorative Therapies segments, and an anticipated acceleration in Pain Treatments in the second half of the year. Additionally, Bioventus emphasized the promising expansion opportunity presented by its recent 510(k) clearance for StimTrial and TalisMann in the peripheral nerve stimulation market, which is projected to grow over 20% annually in the U.S.

Bioventus Financial Statement Overview

Summary
Bioventus faces challenges with declining revenue and profitability, as reflected in its income statement. The balance sheet shows high leverage, which could pose financial risks if not managed properly. On the positive side, the company has improved its free cash flow, which is a critical factor for sustaining operations. Overall, while there are improvements in cash flow, the company needs to address its revenue decline and leverage to enhance financial stability.
Income Statement
45
Neutral
Bioventus has shown a declining revenue trend with a negative revenue growth rate of -62.7% in the TTM period. The gross profit margin remains relatively stable at around 67%, but the net profit margin is negative, indicating ongoing profitability challenges. The EBIT and EBITDA margins have improved slightly in the TTM period but remain low, reflecting operational inefficiencies.
Balance Sheet
50
Neutral
The company has a high debt-to-equity ratio of 2.34, indicating significant leverage. The return on equity is negative, suggesting that the company is not generating sufficient returns on its equity base. The equity ratio is not provided, but the high leverage poses potential financial risks.
Cash Flow
55
Neutral
Bioventus has shown a positive free cash flow growth rate of 42.5% in the TTM period, indicating improved cash generation. However, the operating cash flow to net income ratio is low, suggesting that cash flow from operations is not strongly supporting net income. The free cash flow to net income ratio is relatively high, indicating that free cash flow is a significant component of net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue564.14M573.28M512.35M512.12M430.90M321.16M
Gross Profit381.35M388.23M328.19M331.08M302.71M233.52M
EBITDA84.42M-49.55M-23.07M-121.61M45.48M52.06M
Net Income-158.00K-33.54M-156.23M-158.70M19.38M16.41M
Balance Sheet
Total Assets706.79M727.96M810.91M1.37B1.23B494.47M
Cash, Cash Equivalents and Short-Term Investments32.91M41.58M36.96M30.19M43.93M86.84M
Total Debt341.24M335.63M394.85M418.07M357.68M188.38M
Total Liabilities505.49M542.35M589.79M960.43M692.07M350.31M
Stockholders Equity161.24M147.94M173.59M325.24M458.92M144.16M
Cash Flow
Free Cash Flow34.10M37.79M7.98M-25.06M15.62M51.13M
Operating Cash Flow36.24M38.80M15.34M-13.54M22.99M71.80M
Investing Cash Flow21.84M22.96M15.81M-116.44M-283.76M-20.50M
Financing Cash Flow-56.21M-54.58M-26.65M62.08M273.37M-29.57M

Bioventus Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6.92
Price Trends
50DMA
6.95
Negative
100DMA
6.83
Positive
200DMA
8.29
Negative
Market Momentum
MACD
-0.03
Positive
RSI
46.18
Neutral
STOCH
27.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVS, the sentiment is Negative. The current price of 6.92 is below the 20-day moving average (MA) of 7.14, below the 50-day MA of 6.95, and below the 200-day MA of 8.29, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 46.18 is Neutral, neither overbought nor oversold. The STOCH value of 27.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BVS.

Bioventus Risk Analysis

Bioventus disclosed 77 risk factors in its most recent earnings report. Bioventus reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Bioventus Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
809.82M-163.67-4.15%17.17%72.68%
63
Neutral
640.21M-25.33-18.51%22.93%43.83%
54
Neutral
586.88M-4.64-26.99%4.84%0.85%
53
Neutral
$573.79M-0.10%5.08%99.38%
52
Neutral
485.17M-10.54-11.75%26.08%-63.67%
51
Neutral
562.86M-1.19-59.67%1.48%-6091.13%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BVS
Bioventus
6.92
-4.13
-37.38%
OFIX
Orthofix
14.75
-0.63
-4.10%
VREX
Varex Imaging
12.15
0.35
2.97%
KIDS
OrthoPediatrics
18.94
-7.22
-27.60%
SIBN
SI-Bone
14.26
0.45
3.26%
ZIMV
ZimVie Inc
18.90
3.31
21.23%

Bioventus Corporate Events

Business Operations and StrategyPrivate Placements and Financing
Bioventus Secures $400 Million Credit Agreement
Positive
Aug 4, 2025

On July 31, 2025, Bioventus LLC entered into a $400 million credit agreement with Wells Fargo Bank and other financial institutions. The agreement includes a $100 million revolving credit facility and a $300 million term loan, which will be used to refinance existing credit facilities. The credit facilities, secured by the company’s assets, will mature in 2030 and include various financial covenants and interest rates adjusted based on the company’s leverage ratio. This strategic financial move is expected to strengthen Bioventus’s financial position and operational flexibility.

The most recent analyst rating on (BVS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Bioventus stock, see the BVS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 20, 2025